ONKOLOGIK BEMORLARDA DORI VOSITALARI KELTIRIB CHIQARADIGAN QT INTERVALINING UZAYISHI: DIAGNOSTIKA VA DAVOLASH STRATEGIYALARI
Keywords:
QT intervalining uzayishi, kardiotoksiklik, onkologik bemorlar, elektrokardiografiya, ventrikulyar aritmiyalar, antineoplastik terapiya, elektrolit disbalansi, dori vositalari.Abstract
Ushbu maqolada onkologik bemorlarda dori vositalari ta’sirida QT intervalining uzayishi, uning rivojlanish mexanizmlari, klinik ahamiyati hamda diagnostika va davolash strategiyalari yoritilgan. QT intervalining uzayishi antineoplastik terapiya fonida yuzaga keladigan muhim kardiotoksik asoratlardan biri bo‘lib, yurak repolyarizatsiya jarayonining buzilishi bilan bog‘liq. Maqolada ushbu holatning elektrokardiografik aniqlanishi, xavf omillari va og‘ir aritmiyalar, jumladan Torsade de pointes rivojlanish xavfi tahlil qilingan. Shuningdek, klinik amaliyotda erta diagnostika va profilaktik yondashuvlarning ahamiyati ko‘rsatib berilgan.
References
1. Roden D.M.Drug-induced prolongation of the QT interval.New England Journal of Medicine, 2004; 350: 1013–1022.
2. Viskin S.Long QT syndromes and torsade de pointes.The Lancet, 1999; 354(9190): 1625–1633.
3. Schwartz P.J., Crotti L., Ackerman M.J.Genetic basis of cardiac arrhythmias.Circulation Research, 2013; 112(4): 700–714.
4. European Society of Cardiology (ESC) Guidelines2022 ESC Guidelines on cardio-oncology.European Heart Journal, 2022.
5. Zamorano J.L. et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity.European Heart Journal, 2016; 37(36): 2768–2801.
6. CredibleMeds®.QTDrugs List: Drugs associated with QT prolongation and Torsades de Pointes.Arizona Center for Education and Research on Therapeutics (AZCERT), 2025.
7. Lencioni M., et al.Cancer therapy–induced QT prolongation: mechanisms and management.Journal of Clinical Oncology, 2018.
8. Cardinale D., et al.Cardiotoxicity of anticancer treatments: prevention and management.European Heart Journal Supplements, 2020.
